Mostrar el registro sencillo del ítem
dc.contributor.author | Vásquez, Ximena | |
dc.contributor.author | Sánchez-Gómez, Pilar | |
dc.contributor.author | Palma, Verónica | |
dc.date.accessioned | 2021-08-26T19:00:27Z | |
dc.date.available | 2021-08-26T19:00:27Z | |
dc.date.issued | 2021-07-31 | |
dc.identifier.citation | Int J Mol Sci . 2021 ;22(15):8248. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/13320 | |
dc.description.abstract | Glioblastoma (GBM) is the most aggressive and common primary tumor of the central nervous system. It is characterized by having an infiltrating growth and by the presence of an excessive and aberrant vasculature. Some of the mechanisms that promote this neovascularization are angiogenesis and the transdifferentiation of tumor cells into endothelial cells or pericytes. In all these processes, the release of extracellular microvesicles by tumor cells plays an important role. Tumor cell-derived extracellular microvesicles contain pro-angiogenic molecules such as VEGF, which promote the formation of blood vessels and the recruitment of pericytes that reinforce these structures. The present study summarizes and discusses recent data from different investigations suggesting that Netrin-1, a highly versatile protein recently postulated as a non-canonical angiogenic ligand, could participate in the promotion of neovascularization processes in GBM. The relevance of determining the angiogenic signaling pathways associated with the interaction of Netrin-1 with its receptors is posed. Furthermore, we speculate that this molecule could form part of the microvesicles that favor abnormal tumor vasculature. Based on the studies presented, this review proposes Netrin-1 as a novel biomarker for GBM progression and vascularization. | es_ES |
dc.description.sponsorship | This work was supported by: FONDECYT # 1140697 (VP) and Ministerio de Ciencia, Innovación y Universidades and FEDER funds (RTI2018-093596) (PSG). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Netrin-1 | es_ES |
dc.subject | Exosomes | es_ES |
dc.subject | Glioblastoma | es_ES |
dc.subject | Neovascularization | es_ES |
dc.subject | Pericytes | es_ES |
dc.subject | Transdifferentiation | es_ES |
dc.title | Netrin-1 in Glioblastoma Neovascularization: The New Partner in Crime? | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 34361013 | es_ES |
dc.format.volume | 22 | es_ES |
dc.format.number | 15 | es_ES |
dc.format.page | 8248 | es_ES |
dc.identifier.doi | 10.3390/ijms22158248 | es_ES |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
dc.contributor.funder | Fondo Nacional de Desarrollo Científico y Tecnológico (Chile) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1422-0067 | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/ijms22158248 | es_ES |
dc.identifier.journal | International Journal of Molecular Sciences | es_ES |
dc.repisalud.centro | ISCIII::Instituto de Investigación de Enfermedades Raras | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RTI2018-093596 | es_ES |